# Amylyx (AMLX) — News

AMLX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/amlx/news

## Recent headlines

- [Amylyx Pharmaceuticals, Inc.: Citigroup raises target price to $39 from $32](https://www.ainvest.com/news/amylyx-pharmaceuticals-citigroup-raises-target-price-39-32-2610) — AInvest Wire, Oct 15, 2026
- [Trading halt: Aztr (AMEX) - Regulatory concern](https://www.ainvest.com/news/trading-halt-aztr-amex-regulatory-concern-2610) — AInvest Wire, Oct 13, 2026
  On October 13, 2026, trading for Aztr (AMEX) was temporarily suspended amid regulatory concerns, according to reports. While no official statement has been issued by the New York Stock Exchange, the halt has raised questions among investors about the company’s compliance status and operational…
- [ABionyx Pharma SA: Stifel initiates coverage with buy rating; price target EUR 8.5](https://www.ainvest.com/news/abionyx-pharma-sa-stifel-initiates-coverage-buy-rating-price-target-eur-8-5-2609) — AInvest Wire, Sep 17, 2026
  Stifel has initiated coverage of ABionyx Pharma SA (ticker: AMLX) with a "Buy" rating and a price target of EUR 8.50, according to recent market updates. The firm’s decision follows a comprehensive review of the company’s pipeline, financial position, and strategic direction. While no detailed…
- [Amylyx Pharmaceuticals - Bachem manufacturing agreement has initial 5 year term, auto-renews for 3 years, unless earlier terminated with its terms](https://www.ainvest.com/news/amylyx-pharmaceuticals-bachem-manufacturing-agreement-initial-5-year-term-auto-renews-3-years-earlier-terminated-terms-2609) — AInvest Wire, Sep 8, 2026
- [Amylyx Pharmaceuticals - To pay $30 mln upfront fee to Polypeptide for capacity reservation - SEC filing](https://www.ainvest.com/news/amylyx-pharmaceuticals-pay-30-mln-upfront-fee-polypeptide-capacity-reservation-sec-filing-2609) — AInvest Wire, Sep 8, 2026
  Amylyx Pharmaceuticals has entered into an agreement with Polypeptide Laboratories, Inc., under which it will pay a $30 million upfront fee to reserve manufacturing capacity, according to a recent SEC filing [1]. The agreement is part of Amylyx's strategy to secure production capabilities for its…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).